Document text
Principal Investigator: John Joseph Rossi
Organization: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
Fiscal Year: 2021
Award: $396,000
Funding agency: National Institute of Allergy and Infectious Diseases
Project Abstract
Despite various antiviral agents or symptom-alleviating interventions under development, unfortunately no
effective drug treatment for COVID-19 have been readily identified so far. Given the desperate need for and
willingness to try new therapeutic approaches during the COVID-19 pandemic, RNA-based therapeutics could
prove to be an attractive option due to their rational design and relatively faster speed of development compared
to conventional strategies. Utilizing our extensive experience and expertise in nucleic acid aptamer technology,
we will seek to design and develop RNA aptamer-based drug candidates that can provide immediate neutralizing
protection against SARS-CoV-2 infection. The SARS-CoV-2 binds to human angiotensin I converting enzyme 2
(ACE2) through its trimeric spike protein (S protein) on the virion, where after fusion of the viral membrane and
host cell membrane occurs. Subsequently, the RNA virus will replicate its genome inside the cells and ultimately
make new virions that will be secreted to infect other host cells. The S protein is the key target for the
development of neutralizing antibodies (Abs), vaccine and therapeutics. The immediate objective of our project
is to develop novel inhaled RNA aptamers that specifically bind to the conserved and functional essential
elements of SARS-CoV-2 S protein, as viral neutralizing agents, to prevent viral entry and infection. Our central
hypothesis is that the inhaled neutralizing RNA intervention will have utility for both pre-exposure prophylaxis
and immediate post-exposure treatment to provide a 1st line of defense against SARS-CoV-2 and/or future
SARS-CoV stains. In addition to their utility as stand-alone antagonists, the aptamer can also be formulated as
cocktailed format or multivalent modality to maximize neutralization potency and breadth. The inhalation
administration will further maximize delivery to the epithelial cilial cells of the upper and lower respiratory tract,
the tissue sites of initial viral attachment and infection. To the end, we expect successful completion to lead to a
translational stage and justify the use of inhaled neutralizing RNA therapeutics immediately in the clinic to protect
1st line health care workers and others at high risk of SARS-CoV-2 exposure. The proposed research is both
significant and innovative, and could change current paradigms in the treatment of SARS-CoV-2 infection. The
knowledge gained from this study can be rapidly deployed for combating a future strain evolution of SARS that
may emerge as a human healthcare threat.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Aerosols><Affinity><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Animal Model><Animal Models and Related Studies><Antibodies><Antigenic Determinants><Antiviral Agents><Antiviral Drugs><Antivirals><Aptamer Technology><Avidity><Binding><Binding Determinants><Binding Sites><Bio-Informatics><Bioinformatics><Body Tissues><CD143 Antigens><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Carboxycathepsin><Case Fatality Rates><Cell Body><Cell Communication><Cell Interaction><Cell membrane><Cell-to-Cell Interaction><Cells><Charge><Chemicals><China><Clinic><Clinical><CoV-2><CoV2><Combining Site><Communities><Cultured Cells><Cytoplasmic Membrane><Development><Dipeptidyl Peptidase A><Disease><Disease Progression><Disorder><Dose><Drug Delivery><Drug Delivery Systems><Drug Therapy><Drugs><Elements><Engineering><Epithelial><Epitopes><Evolution><Formulation><Future><Generations><Genetic Alteration><Genetic Change><Genetic defect><Genome><Health><Health Care Providers><Health Personnel><Healthcare><Healthcare Providers><Healthcare worker><Human><Immune response><Immunological response><In Vitro><Infection><Inhalation><Inhalation Administration><Inhalation Drug Administration><Inhalation Route of Drug Administration><Inhaling><Intervention><Intervention Strategies><Kininase A><Kininase II><Knowledge><Lead><Lower respiratory tract structure><Mainland China><Masks><Measures><Mediating><Medication><Membrane><Mice><Mice Mammals><Modality><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Mutation><Nasal><Nasal Passages Nose><Nature><Non-Polyadenylated RNA><Nose><Nucleic Acids><Pathway interactions><Pb element><Penetration><Peptidyl-Dipeptidase A><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacotherapy><Plasma Membrane><PrEP><Preparedness><Prophylactic treatment><Prophylaxis><Proteins><Pulmonary Body System><Pulmonary Organ System><RNA><RNA Gene Products><RNA Nucleases><RNA Viruses><RNase><Reactive Site><Readiness><Research><Resistance><Respiratory Drug Administration><Respiratory Infections><Respiratory System><Respiratory System, Nose, Nasal Passages><Respiratory Tract Infections><Respiratory Tracts><Respiratory tract structure><Ribonuclease Family Protein><Ribonucleases><Ribonucleic Acid><Risk><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Saline><Saline Solution><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Site><Specificity><Speed><Staining method><Stains><System><Technology><Testing><Therapeutic><Time><Tissues><Transgenic Mice><Tube><Vaccines><Viral><Viral Burden><Viral Diseases><Viral Load><Viral Load result><Virion><Virus Diseases><Virus Particle><Virus Replication><Wuhan coronavirus><aerosolized><alleviate symptom><ameliorating symptom><anti-viral agents><anti-viral drugs><anti-viral efficacy><anti-virals><antiviral efficacy><aptamer><base><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><combinatorial><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><decrease symptom><deep sequencing><design><designing><develop a vaccine><development of a vaccine><developmental><disease severity><drug candidate><drug inhalation><drug treatment><drug/agent><experience><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><fewer symptoms><genome mutation><hCoV19><health care><health care personnel><health care worker><health provider><health workforce><healthcare personnel><heavy metal Pb><heavy metal lead><high risk><host response><immune system response><immunoresponse><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><interventional strategy><lower respiratory tract><medical personnel><membrane structure><model of animal><model organism><mouse model><murine model><nCoV2><neutralizing antibody><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pandemic><pandemic disease><pandemic preparedness><pathway><plasmalemma><pre-exposure prophylaxis><prevent><preventing><prophylactic><receptor binding><receptor bound><reduce symptoms><relieves symptoms><resilience><resistant><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><symptom alleviation><symptom reduction><symptom relief><therapeutic RNA><therapeutic agent development><therapeutic development><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment provider><vaccine development><vaccine formulation><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease><willingness>